Search results for: Chronic Diseases
Filter search results
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
…a paradigm shift in medicine, offering the potential for significant improvements in both quality and longevity of life, by addressing the root genetic causes of diseases. Due to this potential…
OHE submission to the UK Parliamentary Inquiry on an Ageing Society
20 May 2025
…the burden of vaccine-preventable diseases is projected to rise, and undervaluation can lead to underfunding and hence threaten societal welfare. Finally, the UK’s uptake of adult vaccines that are widely…
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
…by the context of the submission, such as disease area, intervention type, and expected clinical impact. COAs tend to be more relevant in submissions for chronic and rare diseases. More…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Share this: Download publication Henry Fong Patricia Cubi-Molla Martina Garau Key messages Novel administration devices, once considered supplementary in biologic-device combinations, may gain strategic importance as subcutaneous biologic injections become…
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
Share this: Download publication Priscila Radu Conchi Biurrun Meindert Boysen Melanie Whittington Chris Skedgel Key messages Current HTA processes often adopt a narrow healthcare payer perspective, focusing on direct system…
Access to Orphan Drugs in the EU
21 October 2010
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr Mestre-Ferrandiz reported on OHE…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
…can be resolved’. Four groups of issues are identified. Recent surveys appear to suggest that the general public would not necessarily allocate more resources to those with orphan diseases than…
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
…diseases (‘orphan drugs’) has generated considerable debate. While there is debate in the economic literature over whether a premium should be paid for ‘rarity’, these drugs are reimbursed with high…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases, and ‘cures’ for conditions…